Drug Type T-lymphocyte cell therapy |
Synonyms CD19/CD22 dual target therapy (Eureka Therapeutics) |
Target |
Action inhibitors |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), CD22 inhibitors(CD22 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| B-Cell Lymphoma | Preclinical | United States | - | |
| Lymphoid Leukemia | Preclinical | United States | - |





